WhelWomen's Health Evidence Lab
Home/Full index (preview)/WHEL-C-092
WHEL-C-092 · Emerging evidence · 5/10

myo-inositol + oral contraceptive pill for PCOS

In a single small follow-up study of lean PCOS teenagers, myo-inositol combined with oral contraceptives prevented increases in weight and BMI and improved metabolic and hormonal parameters.

Origin · Existing drug · repurposing candidatePathway · 505(b)(2) · existing active ingredient, new indicationEvidence arm · Direct researchEvidence supports
How to read thisThe summary above and the proposed mechanism are generated by the model from the sources it ingested, and are written as the model’s reasoning rather than established fact. Any figure quoted from MATRIX is a model-derived association score, not a clinical measurement. How far the published record backs this pair is carried by the score’s own rigor dimension and traced to verbatim sources at the foot of the page.

Hypothesized mechanism

Myo-inositol acts as an insulin sensitizer, potentially improving metabolic and hormonal profiles in PCOS when added to OCP therapy.

This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.

How the score was reached, for this pair

The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 5 of 10 overall, a emerging reading, from a direct rated emerging in strength.

The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.

Direct research arm · anchors the headline5.0 / 10 · Emerging

Scored for women. Evidence generated in women (female population, ~100% female). (band F1, ×1.00).

Corroboration

All four claims derive from a single primary study on lean PCOS teenagers. There is no independent corroboration from additional studies, so this scores at the bottom of the single-primary-study range.

0 / 2

Rigor

The source is a follow-up comparison study in a small population of teenagers (ages 17-19), consistent with a small comparative trial rather than a large RCT or meta-analysis. No randomization, blinding, or sample size is described, so this is observational/small-trial level.

1 / 2

Specificity

Both the intervention (myo-inositol combined with OCP) and the condition (PCOS) are named directly in the claims and source title. The specificity is unambiguous.

2 / 2

Plausibility

The claims assert improvements in metabolic and hormonal parameters, which is mechanistically plausible since myo-inositol is an insulin-sensitizing agent relevant to PCOS pathophysiology. However, no explicit mechanistic pathway is evidenced in the quotes, so this is plausible but not evidenced.

1 / 2

Consistency

All claims come from a single study, so cross-study consistency cannot be assessed. Per the n/a rule, this is scored 1 and not penalized.

1 / 2
How the scoring rubric works, in general →

Layers not covered for this pair

Sex-specific pharmacokineticsNone on file

Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.

More on the sex-specific pharmacokinetics layer and its sources →
Cycle-phase dependenceNone on file

Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.

More on the cycle-phase layer and its sources →

Source evidence · what the pipeline ingested

These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).

Every source below belongs to this signal’s evidence arm, Direct research. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.

These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.

The primary sources and pipelines this evidence is drawn from →
← Back to the full index